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Abstract
Background: Human adenoviruses (Ads) have substantial potential for clinical applications in cancer patients.
Conditionally replicating adenoviruses (CRAds) include oncolytic adenoviruses in which expression of the immediate
early viral transactivator protein E1A is controlled by a cancer cell-selective promoter. To enhance efficacy, CRAds are
further armed to contain therapeutic genes. Due to size constraints of the capsid geometry, the capacity for packaging
transgenes into Ads is, however, limited. To overcome this limitation, the employment of E1A-deleted replication-
deficient viruses carrying therapeutic genes in combination with replication-competent CRAd vectors expressing E1A
in trans has been proposed. Most trans-complementing studies involved transgene expressions from strong ubiquitous
promoters, and thereby relied entirely on the cancer cell specificity of the CRAd vector.
Results: Here we tested the trans-complementation of a CRAd and a replication-deficient transgene vector containing
the same cancer cell-selective promoter. Hereto, we generated two new vectors expressing IL-2 and CD40L from a
bicistronic expression cassette under the control of the melanoma/melanocyte-specific tyrosinase enhancer tyrosinase
promoter (TETP), which we previously described for the melanoma-specific CRAd vector AdΔEP-TETP. These vectors
gave rise to tightly controlled melanoma-specific transgene expression levels, which were only 5 to 40-fold lower than
those from vectors controlled by the nonselective CMV promoter. Reporter analyses using Ad-CMV-eGFP in
combination with AdΔEP-TETP revealed a high level of trans-complementation in melanoma cells (up to about 30-fold),
but not in non-melanoma cells, unlike the AdCMV-eGFP/wtAd5 binary vector system, which was equally efficient in
melanoma and non-melanoma cells. Similar findings were obtained when replacing the transgene vector AdCMV-eGFP
with AdCMV-IL-2 or AdCMV-CD40L. However, the combination of the novel AdTETP-CD40L/IL-2 vector with AdΔEP-
TETP or wtAd5 gave reproducible moderate 3-fold enhancements of IL-2 by trans-complementation only.
Conclusions: The cancer cell-selective TETP tested here did not give the expected enforceable transgene
expression typically achieved in the Ad trans-complementing system. Reasons for this could include virus-mediated
down regulation of limiting transcription factors, and/or competition for such factors by different promoters.
Whether this finding is unique to the particular promoter system tested here, or also occurs with other promoters
warrants further investigations.
Introduction
Cancer immunotherapy is an experimental approach for
treatment of cancer patients. It aims at evoking
immune-based responses against malignant cells by acti-
vating and recruiting cells from the innate and adaptive
immune system, including T cells that recognize tumor-
specific antigens [1]. Virus-mediated gene transfer has
been widely used to enhance the susceptibility of cancer
cells to immunotherapy. Therapeutic genes expressed by
viral vectors included a broad number of immune mod-
ulators, such as e.g. granulocyte macrophage colony sti-
mulating factor (GM-CSF), interleukin-2 (IL-2),
interferons or CD40 ligand (CD40L) [2-4]. These
approaches have proven to be inefficient, however, since
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co-stimulatory molecules necessary for induction of cel-
lular immunity, and evade immune recognition. An
additional major limitation of cancer immunotherapy
has been the low rates of gene transfer.
Strategies to improve both, the potency of immune
recognition of cancer cells and the efficacy of gene ther-
apy are clearly required to successfully employ the pro-
mising concept of cancer immunotherapy. One way to
enhance the duration of therapeutic gene expression is to
increase viral spreading [5], for example by replacing
non-replicating therapeutic virus vectors with armed
oncolytic viruses, which replicate selectively within can-
cers and also express therapeutic genes [6-8]. Therapeu-
tic genes include prodrug converting enzymes, suicide
genes, and immunostimulatory proteins. The most widely
used oncolytic viral vectors have been derived from non-
integrating parental viruses, such as vaccinia virus, herpes
simplex virus, measles virus and human Ad [9]. Human
Ads have an excellent safety profile in cancer gene ther-
apy [10]. In addition, they are easy to produce in large
amounts, and efficient infection is possible with vectors
derived from various serotypes or by tropism engineering
[11]. The latter is based on the availability of adequate
methods to generate recombinant vectors of choice,
including CRAds for cancer treatment [12,13].
The number of inserted therapeutic genes is, however,
limited for Ad due to the packaging capacity of the viral
capsid [14]. One promising way to overcome this limita-
tion is to use trans-complementing co-replication, where
a CRAd is mixed with a second, E1-deleted and there-
fore replication-deficient (RD) vector expressing the
therapeutic gene(s) of interest. In such a system, the
E1A gene expressed by the first vector complements the
second vector in trans, which gives rise to efficient repli-
cation of both vectors, thereby strongly increasing the
DNA copy number on a per cell basis. This concept was
first confirmed by combining transduction of an E1-
deleted Ad with transfection of a plasmid containing the
E1 genes and subsequent production of progeny virus
and enhanced viral transgene expression [15,16].
Subsequently, numerous variations of the binary virus
system have been tested. The group of Alemany was the
first to combine two defective viruses, a RD E1-deleted
virus and a helper-dependent virus containing the E1
genes under the control of the liver tissue-specific pro-
moter and demonstrated oncolytic spread following
injection of a 1:1 mix into human hepatocarcinoma
mouse xenograft model [17]. Several groups used RD
Ad vectors expressing reporter genes such as b-galacto-
sidase, luciferase or eGFP to show enhancement of virus
replication and cell spreading [18-23]. More recently,
this system has led to new exciting applications for non-
invasive in vivo imaging of tumor spread and assessment
of Ad replication [24-27]. Therapeutic genes utilized in
binary vector systems included prodrug converting
enzymes such as herpes simplex virus-thymidine kinase
[28,29] and P450 enzyme [21], suicide genes like Bcl-xs
[30], p53 [31,32], p27 [25], tumor necrosis factor a-
related apoptosis-inducing ligand [23,33-36], dominant-
negative insulin-like growth factor-1R [22], antiangio-
genic soluble vascular endothelial growth factor receptor
2-Fc [26,37], and immunostimulatory proteins like GM-
CSF [33,38], IL-2 and IL-12 [39]. In most studies, co-
administration of RD therapeutic vectors and CRAds
was also tested in in vivo xenotransplant models.
Improved oncolytic efficacy was found and in some
cases lead to complete and long lasting regression,
which was not achieved when using the individual viral
vectors alone [21-26,28,29,33-37,39].
The currently available dual vector co-replication sys-
tems control the expression of the therapeutic genes by
strong ubiquitous promoters lacking tissue or tumor spe-
cificity. In this study we suggested to combine a CRAd
and a RD vector containing the same cancer cell-selective
promoter, and to test, whether a strong enhancement of
transgene expression can be achieved by trans-comple-
mentation. The results presented here show that when
using the cancer cell-selective TETP promoter previously
described for our melanoma/melanocyte-specific CRAd
vector [40] in combination with two novel RD vectors
expressing IL-2 and CD40L from a bicistronic expression
cassette, only moderate 3-fold enhancements of IL-2 or
CD40L were obtained, whereas controls including the
CMV promoter allowed much stronger expression
enhancement in the Ad vector co-replication system.
Possible reasons for this finding are discussed.
Materials and methods
Cells
The primary melanoma short time culture cells
M000301 were grown in RPMI 1640 plus 8% FCS [41].
All other cell lines including the human embryonic
retina cell line 911, the human lung carcinoma cell line
A549, the human cervical carcinoma cell line HeLa and
the human colon carcinoma cell lines SW480, DLD-1,
the human melanoma cell lines M21-L4, MeWo and
S K - M e l 2 3w e r eg r o w ni nD M E Mp l u s8 %F C S
[40,42,43]. All cell lines were routinely screened for the
absence of mycoplasma contamination.
Viruses
The recombinant, first-generation, E1/E3-deleted Ad5-
based vectors AdTETP-IL-2/CD40L and AdTETP-
CD40L/IL-2 expressing mouse IL-2 and CD40L were
generated as described previously [42]. Briefly, homolo-
gous recombination was performed in 911 cells between
a transfer plasmid containing the transgene under the
Fontecedro et al. Virology Journal 2010, 7:175
http://www.virologyj.com/content/7/1/175
Page 2 of 17control of TETP and a genomic Cla ID N Af r a g m e n t
isolated from AdMLP-lacZ. To generate the transfer
plasmids, a Kpn I- Bgl II (blunt) TETP fragment of 1197
bp was released from the pGL3-4xTETP plasmid [40]
and was cloned in a first step into the Kpn I- Bam HI
(blunt)-restricted transfer plasmid pAdCMVΔlacZ-lnk1
to replace the CMV promoter. The resulting pAdTET-
PΔlacZ-lnk1 carried an E1 deletion from bp 449 to
3323. For the generation of the two bicistronic expres-
sion cassettes, the IL-2 and CD40 ligand-encoding frag-
ments were linked by an internal ribosomal entry site
(IRES) derived from encephalomyocarditis virus [44].
For this, the CD40L sequence was PCR-amplified using
the forward primer 5′-GCGCATGCGGTCTCCCATGA-
TAGAAACATACAGCCAAC-3′ and the reverse primer
5′-GCGCCTCGAGTGCAGCCTAGGACAGCGCACTG-
3′, introducing a terminal Bsa I site with a Nco Io v e r -
hang-matching sequence at the 5′-end and a terminal
Xho I site at the 3′-end. The Bsa I-Xho I fragment was
cloned between the Nco I-Xho I-digested pBlusecript-
IRES [44]. In a second step, a Pst I( b l u n t )-Spe I
(blunt) IL-2 sequence containing fragment was cloned
into the Xba I-digested (blunt) pBlusecript-IRES-CD40L.
For the generation of the inverse construct, the IL-2
sequence was first PCR-amplified using the forward pri-
mer 5′-GCGCATGCGGTCTCGCATGTACAGCATG-
CAGCTCG-3′ and the reverse primer 5′-GCGCCTCGA
GGAGCCTTATGTGTTGTAAGCAG-3′, followed by
the same cloning strategy as above. A Pst I (blunt) - Sal
I (blunt) CD40L sequence containing fragment was
cloned into the Xba I-digested (blunt) pBlusecript-IRES-
IL-2. For the final ligation, the Not I (blunt) - Spe I frag-
ments of IL-2-IRES-CD40L and CD40L-IRES-IL-2 were
cloned into the Asc I( b l u n t )-Nhe I- digested pAd-
TETP.
Recombinant Ads were once plaque-purified, ampli-
fied and CsCl-purified. Viral titers were determined by
plaque assay using 911 cells. Biological titers varied
between 3 × 10
9 and 3 × 10
10 plaque forming units
(pfu)/ml, when determined in a standard assay using
2 ml of medium and the cell layers contained in 6-well
plates. For AdΔEP-TETP, AdCMV-lacZ, AdCMV-IL-2,
AdCMV-CD40L, AdCMV-eGFP see references in
Table 1.
Expression analyses
For mouse CD40L and IL-2 expression analysis, tripli-
cates of 1 × 10
5 cells seeded in 12-well plates were
infected at multiplicities of infection (MOIs) ranging
from 10 to 810. Medium was replaced 5 h post infection
(p.i.) and cells were analyzed two days p.i.. Levels of
CD40L were determined by flow cytometric analysis as
described earlier [42] using R-PE-labeled anti-mouse
CD40L (CD154) (09025B) and appropriate isotype con-
trols (Pharmingen, San Diego, USA). FACS measure-
ments consisted of 10000 viable cells per sample. Mouse
IL-2 levels were determined in duplicates by ELISA
(Mouse IL-2 kit, PIERCE ENDOGEN) using pooled
samples.
For RT-PCR of Microphthalmia-associated bHLH-LZ
transcription factor (Mitf), total RNA was extracted
using TRIzol reagent according to manufacturer instruc-
tions (Invitrogen, Carlsbad, CA, USA). One microgram
total RNA was used for cDNA synthesis using Prome-
ga’s Reverse Transcription System with supplied poly d
(T) primers according to manufacturer instructions
( P r o m e g a ,M a d i s o n ,W I ,U S A ) .P C Rw a sp e r f o r m e do n
1 μgt e m p l a t ec D N Au s i n gR o c h e ’s LightCycler DNA
Master SYBR Green kit (Roche, Basel, Switzerland). Pri-
mers for 18sRNA were 5′-AAACGGCTACCACATC-
CAAG-3′ and 5′-CCTCCAATGGATCCTCGTTA -3′.
Primers for Mitf were purchased from Qiagen,
QT00037737 (Qiagen, Hombrechtikon, Switzerland).
Co-replication experiments
Experiments to assess co-replication potency on trans-
gene expression were performed in 12-well plates using
triplicate inputs. Four hours after seeding of 10
5 cells/
well, serial 3-fold dilutions of GFP- or transgene-expres-
sing viruses were added, followed immediately by addi-
tion of varying amounts of replication-competent
viruses. Medium was replaced 5 h p.i. and cells were
Table 1 Adenoviruses used in this study
Virus name E1 region Titer (pfu/ml) Reference
Wt Ad5 WT 1 × 10
11 [40]
AdΔEP-TETP E1A promoter deleted and replaced with TETP 1.4 × 10
10 [40]
AdCMV-lacZ deleted [42]
AdCMV-IL-2 deleted 1.8 × 10
10 [44]
AdCMV-CD40L deleted 1.0 × 10
10 [44]
AdCMV-eGFP deleted 2.6 × 10
9 [43]
AdTETP-IL-2/CD40L TETP inserted downstream of E1A promoter 6.0 × 10
9 This study
AdTETP-CD40L/IL-2 TETP inserted downstream of E1A promoter 5.2 × 10
9 This study
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GFP or CD40L, and by ELISA for IL-2.
Results
Novel Ad vectors containing TETP allow melanoma-
specific CD40L and IL-2 transgene expression
Tissue-specific promoters have been utilized to restrict
expression of transgenes to target tissues, or to restrict
viral replication to targeted cancer cells [45-47]. Here we
intended to restrict Ad-mediated expression of immu-
notherapeutic CD40L and IL-2 genes to melanoma cells
by replacing the CMV promoter of a first-generation, E1/
E3-deleted Ad5-based vector with the melanoma/melano-
cyte-specific TETP (Fig. 1) [40]. Two recombinant vectors
were generated, AdTETP-IL-2/CD40L and AdTETP-
CD40L/IL-2, containing IRES-linked, bicistronic expres-
sion cassettes coding for mouse IL-2 and CD40L. Similar
IRES-linked expression cassettes have been described in
the literature, and it was anticipated that IRES-mediated
second gene expression was lower than first gene expres-
sion [48]. When non-melanoma HeLa or SW480 cells
were transduced with serial 3-fold increasing concentra-
tions of the two novel viruses, no CD40L transgene
expression was detected, even at the highest virus input of
MOI 810 (Fig 2A, B). However, high levels of CD40L
expression were achieved in these cells from control
AdCMV-CD40L vector (Fig 2C). Of note, SW480 cells
required about 80-fold more AdCMV-CD40L to reach
comparable levels as HeLa cells, which are highly Ad sen-
sitive [49]. In contrast to the non-melanoma cells, trans-
duction of melanoma M000301 and M21L4 cells gave rise
to robust CD40L expression with both, AdTETP-IL-2/
CD40L and AdTETP-CD40L/IL-2 (Fig 2A, B). The expres-
sion levels were dependent on the relative CD40L gene
position, as CD40L upstream of the IRES sequence gave
rise to about 10- and 15-fold higher expression levels in
M000301 and M21L4 cells, respectively, than CD40L posi-
tioned downstream of IRES. When using AdCMV-CD40L,
Figure 1 Structures of E1A promoter of wt Ad5, AdΔEP-TETP and E1 region of AdCMV-eGFP, AdTETP-CD40L/IL-2. (A) The first 650 bp of
the wt Ad genome comprising the left ITR, enhancer elements (EI, EII), packaging elements (I-VII), minor (thin arrows) and major (bold arrow)
transcriptional start sites, TATA-box and the beginning of the E1A ORF. (B) Insertion of TETP in combination with duplication of packaging
elements V-VII and deletion of endogenous E1A promoter resulting in AdΔEP-TETP. (C) In AdCMV-eGPF, the deleted E1 region from nt 449 to
3333 is replaced with the CMV-eGPF expression cassette. (D) In AdTETP, the deleted E1 region from nt 449 to 3333 is replaced with the TETP-
CD40L-IRES-IL-2 expression cassette. The nucleotide numbers refer to the corresponding wt sequence.
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Page 4 of 17Figure 2 CD40L transgene expression by different recombinant Ad vectors. Serial 3-fold increasing amounts of AdTETP-IL-2/CD40L (A),
AdCD40L/IL-2 (B), and AdCMV-CD40L (C) were used to transduce HeLa cervical carcinoma, SW480 colon carcinoma, and M000301 and M21L4
melanoma cells for 5 h. Cells were then washed, and CD40L was analyzed two days p.i. by flow cytometry. Results are shown as mean
fluorescence intensity (MFI) of triplicate measurements. (D) Transduction of M000301 cells with AdCD40L/IL-2 without washing off virus. Analysis
was performed as described for A-C.
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higher expression levels in M000301 and M21L4 cells,
respectively, compared to the expression levels achieved
with the AdTETP-CD40L/IL-2 vector. The transduction
procedure applied here included virus inoculation for 5 h,
followed by removal of the virus. In the virus input range
from MOI 10 to 270, expression levels of CD40L could be
further increased by a factor of 2 to 3 when the inoculum
was not removed (Fig. 2B, D), in agreement with a 5 h
virus adsorption efficiency of about 50% [50].
In a next step, IL-2 concentrations contained in the
supernates of the above transduced HeLa and
M000301 cells were determined. In supernates of HeLa
cells, AdTETP-IL-2/CD40L of MOI 10 to 810 gave rise
to IL-2 levels from 29 to 144 pg/ml (Fig. 3A). IL-2
production from AdTETP-CD40L/IL-2 was in the
range of 36 to 424 pg/ml (Fig. 3B). In supernates of
melanoma M000301 cells, both viruses led to very
similar expression levels from 5 × 10
3 to 7 × 10
5 pg/
ml (Fig. 3A, B). Thus, for MOIs of 10 and 810,
AdTETP-IL-2/CD40L-mediated IL-2 expression levels
were 177- and 5652-fold higher in M000301 cells com-
pared to HeLa cells. For AdTETP-CD40L/IL-2, the
values were 149- and 1533-fold higher. In contrast to
t h eC D 4 0 Lg e n e ,n oc o n s i s t e n ti n f l u e n c eo ft h eI L - 2
gene position was noticed for IL-2 expression in the
two different cell types. Of note also, detection of low
IL-2 amounts in supernates of HeLa cells, as opposed
to undetectable CD40L expression in these cells, is
most likely explained by the difference of sensitivity
and/or dynamic range of the assay systems used here.
AdCMV-mediated IL-2 expression levels were compar-
able in the two cell lines tested (Fig. 3C) and reached a
minimal 5- to a maximal 12- fold higher levels in mel-
anoma M000301 when compared to TETP-mediated
expression levels in these cells. In HeLa cells, AdCMV-
mediated IL-2 expression levels were between 1544-
and 53472-fold higher compared to TETP-mediated
expression levels.
In summary, replacement of the ubiquitously active
and strong CMV enhancer promoter with the mela-
noma/melanocyte-specific enhancer promoter TETP
Figure 3 IL-2 transgene expression by different recombinant Ad vectors. Serial 3-fold increasing amounts of AdTETP-IL-2/CD40L (A),
AdCD40L/IL-2 (B), and AdCMV-IL-2 (C) were used to transduce HeLa cervical carcinoma and M000301 melanoma cells for 5 h. Cells were then
washed, and IL-2 of the supernates was analyzed two days p.i. by ELISA. Results are shown as mean of duplicate measurements.
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transgene expression.
Enhancement of GFP transgene expression by adenovirus
trans-complementation
To determine concentration-dependence and kinetics of
Ad trans-complementation-mediated enhancement of
gene expression, we first used eGFP as a reporter sys-
tem. Initial experiments with each four non-melanoma
and melanoma cell lines revealed strongest co-replica-
tion-mediated enhancement effects in SW480 colon car-
cinoma cells (not shown). In a next step, we used
SW480 cells to determine the kinetics of the enhance-
ment effect in more detail. For this, SW480 cells were
infected with AdCMV-eGFP at MOIs of 0.37, 1.1, 3.3
and 10 alone, or in combination with wtAd5 at concen-
trations ranging from MOI 0.37 to 90, using serial 3-
fold increases (Fig. 4). The resulting ratios of wtAd5/
AdCMV-eGFP amounted to 1, 3, 9, 27, 81 and 243 for
the first set of six samples using AdCMV-eGFP at an
MOI of 0.37. Reporter eGFP expression analyses were
performed at day 1, 2, 3 and 4, and enhancement was
calculated after subtraction of auto-fluorescence of unin-
fected cells (Fig. 4A-D). WtAd5-mediated enhancement
of GFP expression was seen at all four time points, with
highest absolute expression levels at day 2, when
AdCMV-eGFP at MOIs of 0.37, 1.1, 3.3 and 10 alone
resulted in eGFP expression levels of 1.8, 3.1, 5.6 and
15.9 arbitrary mean fluorescence intensity units, respec-
tively. As a result of wtAd5 addition, these expression
levels were enhanced by 123-, 87-, 75-, and 48-fold,
from lowest AdCMV-eGFP input level of MOI 0.37 to
highest AdCMV-eGFP input level of MOI 10. For all
four time points, the enhancement effects were strongest
for the lowest AdCMVe-GFP input of MOI 0.37, and
then gradually decreased with higher input of AdCMVe-
GFP. On the other hand, strongest enhancement corre-
lated with the highest ratio of wtAd5/AdCMV-eGFP
used, except at day 4, where enhancement effects at the
highest ratios started to decline due to cytopathic effects
Figure 4 Concentration-dependence and kinetics of Ad co-replication-mediated enhancement of eGFP expression. SW480 cells were
infected with AdCMV-eGFP at MOIs of 0.37, 1.1, 3.3 and 10 alone (-), or in combination with wtAd5 at concentrations ranging from MOI 0.37 to
90, using serial 3-fold increases. The resulting ratios of wtAd5/AdCMV-eGFP are indicated. eGFP expression analyses were performed at day 1, 2,
3 and 4 p.i. by flow cytometry, and enhancement factors were calculated, following subtraction of auto-fluorescence of uninfected cells (cells
only, co), unless, differences between uninfected and infected cells at MOI 0.37 were statistically not significant (not determined, nd).
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using a ratio of 1:1 for reporter vector to wtAd5, highest
enhancement found was at day 4 amounting to 84-fold
at MOI 10 of each virus.
We then tested the performance of our previously
described melanoma replication-competent (RC) Ad
virus AdΔEP-TETP [40] in trans-complementation-
mediated expression assays. For co-infection, AdCMV-
eGFP at MOIs of 0.37, 1.1, 3.3 and 10 were combined
with RC wtAd5 and AdΔEP-TETP, or as control, the
replication-defective E1-deleted AdCMV-lacZ at concen-
trations ranging from MOI 0.37 to 90, using serial 3-fold
increases as in the previous experiment. Reporter eGFP
expression was recorded at day 2. The tested cells
included HeLa cervical carcinoma cells, SW480 and
DLD-1 colon carcinoma cells, and A549 lung carcinoma
cells, and four melanoma cells M000301, MeWo,
M21L4 and SK-Mel23 (Fig. 5, Table 2).
WtAd5 enhanced expression in all eight cell lines,
although at variable extents depending on the ratios of
RC virus/reporter vector. Enhancement factors were in
the range of 133-fold in SW480 to 3.1-fold in MeWo.
Cells with enhancement factors < 10 included HeLa,
DLD-1, SK-Mel23 and MeWo cells, which all, except
SK-Mel23, revealed relatively high transduction sensitiv-
ity to the lowest dose of MOI 0.37 AdCMV-eGFP virus
input, resulting in 9, 15 and 54 MFI units, respectively
(Table 2). Cells with enhancement factors >10 included
SW480, A549, M000301 and M21L4 and were less
transduction-sensitive at this virus dosage, giving rise to
2.9, 7.4, 3.3, and 3.3 MFI units, respectively. In mela-
noma cells, enhancement mediated by AdΔEP-TETP
was similar, and in three of them even increased, when
compared to wtAd5. In non-melanoma cells, enhance-
ment factors with this virus were about 1.5- to 10-fold
lower, always with the highest RC/reporter vector ratio
used. This residual enhancement effect mediated by the
AdΔEP-TETP CRAd is most likely due to low E1A
expression from this vector, as replacement of the RC
virus with the RD AdCMV-lacZ led to only very minor
enhancement effects on transgene expression. This is in
agreement with findings that traces of E1A expression
are sufficient to induce replication of the therapeutic
vector genome [40,51]. As seen for SW480 cells,
enhancement was again in general strongest at the high-
est ratio of RC/reporter vector used, unless the RC virus
induced cytopahtic effects.
In summary, robust trans-complementation-mediated
reporter expression enhancement was observed using
the CMV-eGFP expression cassette, which, however,
varied considerably depending on cell types and virus
dosages. For melanoma cells, our previously described
melanoma-specific AdΔEP-TETP revealed trans-comple-
mentation enhancement comparable to wtAd5.
Comparison of adenovirus trans-complementation-
mediated enhancement of CD40L and IL-2 from CMV and
TETP promoters
Next we tested whether Ad trans-complementation
also enhanced the expression of the immune modula-
tor genes CD40L and IL-2. In a first experiment,
AdCMV-CD40L (Fig. 6A, B) or AdCMV-IL-2 (Fig. 6C)
at MOI 1.1 were combined with RC wtAd5 and
AdΔEP-TETP, or the RD E1-deleted AdCMV-lacZ at
concentrations ranging from MOI 0.37 to 90 using
serial 3-fold increases. The resulting ratios of RC/
transgene vector were in the range from 0.33 to 27
when including RC viruses, and 0.33 to 81 when
including RD AdCMV-lacZ control virus. At this low
input of CD40L and IL-2 transgene vectors, trans-com-
plementation resulted in high enhancement of immu-
nostimulatory gene expression in both cell lines.
Trans-complementation-mediated maximal expression
enhancement for CD40L was 86-fold in SW480 cells,
and 53-fold in M000301 cells. For IL-2, maximal
enhancement amounted to 288-fold in M000301 cells.
For non-melanoma SW480 cells, a significantly smaller
CD40L expression enhancement was found when
replacing wtAd5 with AdΔEP-TETP. Inclusion of
AdCMV-lacZ as control revealed only very minor
enhancement effects, reaching in M000301 cells about
7 and 5% of wtAd5-mediated enhancement of CD40L
and IL-2 expression, respectively (Fig. 6A, C).
To see whether Ad trans-complementation could also
enhance expression from a vector containing a tissue-
specific promoter, the experiment was repeated with the
transgene vector AdTETP-CD40L/IL-2. In contrast to
the previous experiments, low but consistent enhance-
ment effects were found for the expression of IL-2, and
none for CD40L (Fig. 7A, B). When AdTETP-CD40L/
IL-2 was combined with AdΔEP-TETP in M000301
cells, trans-complementation-mediated enhancement of
IL-2 amounted to 2.4- and 2.3-fold for the two lowest
AdTETP-CD40L/IL-2 virus concentrations of 1.1 and
3.3, respectively. To exclude that the low enhancement
effect is a peculiar feature restricted to M000301 cells,
trans-complementation assays were also conducted in
SK-Mel23 and M21L4 cells, with similar results (data
not shown).
In order to evaluate possible competitions for limited
transcription factors controlling TETP, the experiment
was repeated with wtAd5 replacing AdΔEP-TETP.
Again, no enhancement was seen for CD40L expression,
and low 3.3-, 2.0- and 1.4-fold enhancement factors
were recorded for IL-2 levels at virus inputs of 1.1, 3.3
and 10, respectively (Fig. 7C, D). IL-2 expression levels
decreased for all samples with AdΔEP-TETP ≥ 10, due
to cytopathic effects, whereas for wtAd5, cytopathic
effects appeared in general at higher concentrations of ≥
Fontecedro et al. Virology Journal 2010, 7:175
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Page 8 of 17Figure 5 Comparison of co-replication enhancement by wtAd5 and melanoma RC Ad virus AdΔEP-TETP. The indicated non-melanoma
and melanoma cells were co-infected using AdCMV-eGFP at MOIs of 0.37, 1.1, 3.3 and 10 in combination with RC wtAd5 and AdΔEP-TETP, or the RD
E1-deleted AdCMV-lacZ. Concentrations of the latter viruses were in the range from MOI 0.37 to 90, using serial 3-fold increases and resulting virus
ratios as in Fig. 4. eGFP expression was recorded at day 2 by flow cytometry, and enhancement factors were calculated as in Fig. 4.
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Page 10 of 1730 and were less strong. These findings do not a priori
exclude that competition for an essential transcription
factor is responsible for the low enhancement effect, in
case such a factor is simultaneously involved in control-
ling TETP as well as viral promoters (see discussion).
However, it has earlier been reported that ectopic
expression of Ad E1A resulted in down regulation of
Mitf, which binds to the tyrosinase promoter and is a
member of the basic helix-loop-helix transcription factor
family [52]. We thus tested Mitf levels in infected
M000301 cells by real-time RT-PCR (Fig. 8). Although
not of statistical significance, there was a clear trend for
lower levels of Mitf expression in M000301 cells
infected with the higher concentrations of the E1A-
expressing viruses wtAd5 and AdΔEP-TETP, compared
to E1A-deleted AdCM-lacZ or uninfected cells. As Mitf
expression levels strongly influence activity of the tyrosi-
nase promoter [53], this could contribute to the lack of
strong trans-complemenation enhancement in the TETP
trans-complementation system described here.
Figure 6 Adenovirus co-replication enhancement of immune modulators CD40L and IL-2 expressed from CMV promoter cassette.
Melanoma M000301 or colon SW480 cells were infected with AdCMV-CD40L (A, B), or AdCMV-IL-2 (C), at an MOI of 1.1, and were combined
with 3-fold increasing amounts of RC wtAd5 and AdΔEP-TETP, or the replication-defective E1-deleted AdCMV-lacZ. The resulting ratios of RC/
transgene vector are indicated. CD40L and IL-2 transgene expression analyses were performed two days p.i. by flow cytometry and ELISA,
respectively. Asterisks indicate the level of significance (*P < 0.05; **P < 0.005; for comparison with corresponding wtAd5/AdCMV-CD40L values).
Fontecedro et al. Virology Journal 2010, 7:175
http://www.virologyj.com/content/7/1/175
Page 11 of 17Discussion
Strategies to improve experimental cancer therapy include
co-delivery of RC oncolytic Ads together with RD vectors
expressing therapeutic genes [17,21,22,26,28,30,31,33-39].
There is a large choice of candidate therapeutic genes
that has been evaluated, including tumor-suppressor,
immunomodulatory or cytotoxic genes. Depending on the
type of cytotoxic genes used, premature death of trans-
duced cells was found to reduce replication of oncolytic
viruses, thereby antagonizing the therapeutic efficacy [54].
Genes with indirect antitumor effects such as immune sti-
mulators might thus be advantageous. We have shown
Figure 7 Adenovirus co-replication enhancement of immune modulators CD40L and IL-2 expressed from the tissue-specific TETP
promoter cassette. Melanoma M000301 cells were infected with AdTETP-CD40L/IL-2 at the indicated MOIs and were combined with 3-fold
increasing amounts of RC AdΔEP-TETP (A, B), or wtAd5 (C, D). The resulting ratios of RC/transgene vector are indicated. CD40L and IL-2
transgene expression analyses were performed two days p.i.. This experiment was performed twice, with similar results.
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Page 12 of 17earlier that the combination of IL-2 and CD40L had an
improved efficacy over the use of single agents, when
applied for direct in situ therapy or vaccination therapy in
a mouse melanoma model [44]. Moreover, we showed
that intratumoral injection of an IL-2-expressing Ad vec-
tor could induce tumor regression in patients with
advanced melanoma [3]. The currently 287 ongoing or
closed gene therapy protocols utilizing Ad vectors for can-
cer treatment include 20 protocols with IL-2, and 11 pro-
tocols with CD40L as therapeutic gene, respectively. Five
protocols, mainly for treatment of leukemia, include com-
bined expression of IL-2 and CD40L http://www.wiley.co.
uk/genmed/clinical/.
Utilization of a binary vector system as compared to
direct therapeutic expression from single oncolytic
viruses poses disadvantages, including more demanding
vector manufacturing and clinical handling. On the
other side, possible advantages compared to armed
oncolytic vectors include their flexible application in
combination with an increase of the overall therapeutic
gene capacity of the delivery system. For example, a sin-
gle CRAd can be combined with numerous therapeutic
RD vectors, which have been tested previously as single
agents. Alternatively, efficacy of different CRAds could
be compared side-by-side in combination with the same
therapeutic vector. The binary vectors may also be safer
than single viruses, as the amount of vector expressing
the therapeutic gene can be delayed to later rounds of
virus application, and can, in addition, be dose-adjusted.
Dissemination of the therapeutic vector, however,
remains a risk, in particular if strong ubiquitous promo-
ters are used to control expression. Thorne et al., e.g.,
found that co-injection of an oncolytic AdΔ24 together
with RD CMV promoter/enhancer-controlled luciferase
vector into xenotransplanted tumors not only gave rise
to enhanced and more durable gene expression in the
tumor tissue, but also led to secondary, weaker biolumi-
nescence in the liver [26]. Thus, additional safety mea-
sures are warranted for this kind of approach.
Here we suggest to utilize our previously described
melanoma/melanocyte-specific TETP [40] to control
expression of CD40L/IL-2 from a bicistronic expression
vector. About 30 tissue-specific mammalian promoters
have been evaluated in RC CRAds [47], and many more
were tested for their fidelity to express transgenes from
RD vectors (reviewed in [46]). The quest for such pro-
moters was brought up following the findings that
in vivo, expression from vectors containing the ubiqui-
tously active and strong CMV promoter resulted in effi-
cient transduction that peaked within a few days, but
frequently became undetectable by one month after
injection. These findings were ascribed to either elimina-
tion of viral genomes by the immune system or to
methylation-induced promoter silencing, and it was sug-
gested that this could be overcome by using tissue-
specific mammalian promoters [55,56].
We found that replacement of the CMV enhancer
promoter with the TETP allowed tight melanoma-speci-
fic transgene expression, as IL-2 expression levels
amounted to a minimal 149-fold to a maximal 5652-
fold higher expression levels in melanoma cells com-
p a r e dt oH e L ac e l l s .T h i si sc o m p a r a b l ew i t he a r l i e r
reports, where a recombinant Ad expressing b-Gal
under the control of two copies of the mouse tyrosinase
enhancer in combination with a 770 bp mouse tyrosi-
nase promoter gave rise to 100- to 200-fold higher
expression in melanoma cells compared to non-mela-
noma cells [57]. In our experiments, a comparison of
TETP-controlled transgene expression levels with those
derived from CMV-controlled vectors revealed, depend-
ing on cell line and transgene, 5 to- 40-fold lower
expression levels in melanoma cells. This is in line with
findings that tissue-specific promoters frequently turned
out to be relatively weak promoters compared to CMV
or other strong viral promoters [58]. A slightly different
version of tyrosinase promoter/enhancer combination
has been claimed to reach, at least in a very limited
number of melanoma cells, comparable expression
Figure 8 Mitf RNA expression levels in non-infected (co) and infected cells as measured by RT-PCR. Cells were harvested two days p.i..
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Page 13 of 17levels as from CMV promoter [57], whereas others
found only maximal 1.3% of the CMV promoter-driven
transcriptional activity [59]. In our hands, TETP-con-
trolled luciferase expression was found to give rise to
about 10- to 20-fold higher expression levels compared
to SV40 promoter [40].
Variations in the expression levels of IRES upstream
and downstream genes have been observed previously.
In one study, IRES-dependent second gene expression
has been reported to range from 6 to 100% of the first
gene expression. This was found to be influenced by
several factors, including the choice of optimal/nonopti-
mal Kozak sequence of the ATG start codon, as well as
the particular cell type used for expression [48]. In con-
trast, in IRES-encoding RNA viruses, yields of transla-
t i o np r o d u c tf r o mt h ed o w n s t r e a mI R E S - d e p e n d e n t
cistron were also found to be higher than from the
upstream cistron [60].
When we used the AdCMV-eGFP/wtAd5 binary vec-
tor system, robust trans-complementation-mediated
reporter expression enhancement was obtained in mela-
noma and non-melanoma cells. In our eight cell types
tested, four revealed enhancements in the range of 3 to
10, and four had enhancements larger than 10, with a
maximal 363-fold for SW480 cells on day 4. Such a
strong variation of trans-complementation-mediated
enhancement has been found in other studies, and may
depend on cell type used, exact transgene vector: CRAd
ratio, time point of individual virus additions (variable
in some studies), trans-activation of the CMV promoter
by cellular and viral gene products [51], and most
importantly, also the type and dynamic range of analysis
system utilized for quantification. Enhancement values
of > 50, e.g., were obtained by others when using luci-
ferase assays [22,24,28], ELISA [38,39], and virus pro-
geny titers [19] which have the largest dynamic range.
When replacing the transgene vector AdCMV-eGFP
with AdCMV-CD40L or AdCMV-IL-2, 49- and 131-fold
trans-complementation-mediated transgene expression
enhancement was found in melanoma M000301 cells,
when combined with wtAd5, and 53- and 288-fold
enhancement when combined with AdΔEP-TETP. To
our surprise, combination of the newly established
AdTETP-CD40L/IL-2 with AdΔEP-TETP or wtAd5
revealed an unexpectedly low trans-complementation-
mediated expression enhancement of maximal 3.3 fold
for the more sensitive IL-2 expression analysis. Possible
reasons for this low enhancement effect could include
competition for virus binding, similar entry pathways or
post entry factors such as transcription factors or
nuclear domains for replication. We consider entry
competition unlikely, since trans-complementation with
CMV-promoters from Ad5 capsids was highly efficient.
All viruses tested here utilize the Coxsackie virus B Ad
receptor as attachment receptor and av integrins as
entry receptors [61].
The unique difference between the AdCMV-eGFP and
AdTETP-CD40L/IL-2 vectors relates to the sequences
of the CMV-eGFP and TETP-CD40L/IL-2 expression
cassettes, whereas the rest of the viral genome is identi-
cal (Fig. 1). Transcription factors could be a limiting fac-
tor if they bound in a rate-limiting manner to the TETP
sequence (but not to the CMV enhancer/promoter
sequence), and at the same time also to one of the viral
promoters. The human tyrosinase promoter sequence
consists of the M-box (a conserved element found in
other melanocyte-specific promoters) containing a first
E-box motif, an SP1 site, and a highly conserved CR2
element comprising a second E-box motif and an over-
lapping octamer element [62]. Both E-boxes were
demonstrated to bind the basic helix-loop-helix tran-
scription factor Mitf, which is essential for melanocyte
differentiation. Of note, a related E-box motif is also
contained in the Ad major late promoter (MLP), which
usually is bound by USF, another ubiquitous member of
the basic helix-loop-helix transcription factor family
[ 6 3 ] .B a s e do nb a n ds h i f ta s s a y s ,i tw a sf o u n dt h a tM i t f
a l s oc o u l db i n dt ot h eE - b o xo ft h eM L P ,a n dc o n v e r -
sely, the USF also could bind to the M-box of melano-
cyte-specific promoters [53]. Similarly, band shift assays
with an oligonucleotide containing the SP1 motif of the
tyrosinase promoter were competed by a SP1 motif
found in the Ad EII late promoter [53]. The tyrosinase
enhancer sequence is less clearly characterized, but was
suggested to contain a binding site for a member of the
fos family transcription factor [64]. The strong CMV
enhancer/promoter contains multiple transcription fac-
tor binding sites, including the ubiquitous Sp1 family of
transcription factors, NF-B, retinoic acid nuclear recep-
tors and CREB/ATF [65]. Thus, depending on the cell
type and expression levels of members of the basic
helix-loop-helix transcription factor or SP1 family, com-
petition for such factor(s) could possibly contribute to
the lower enhancement of the Ad trans-complementa-
tion system found here.
However, a more likely explanation relates to the find-
ings by the group of Goding, which reported that ecto-
pic expression of Ad E1A resulted in down regulation of
Mitf in mouse melan-a melanoma cells, leading to
repression of TRP-1 and tyrosinase levels and subse-
quent loss of pigmentation [52]. This repression could
be relieved by over expression of Mitf. We confirmed
down regulation of Mitf transcripts in human M000301
melanoma cells following infection with E1A-expressing
wtAd5 and AdΔEP-TETP, but not with E1A-deleted
AdCMV-lacZ. Whether this is the exclusive mechanism
to explain lack of strong enhancement, or whether there
is an additive effect together with the above discussed
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Page 14 of 17competition for transcription factors remains to be
further studied. In addition, as strong and specific deliv-
ery of therapeutic genes is one of the main goals of can-
cer therapy, it may be of importance for the general
usage of the binary Ad expression system to investigate
whether this finding is unique to the TETP system
tested here, or whether it also occurs with other tissue-
or cell type-specific promoters.
Conclusions
I nt h ec u r r e n ts t u d yw ew e r ea b l et od e m o n s t r a t es t r o n g
in vitro enhancement of eGFP, IL-2 and CD40L transgene
expression by the Ad trans-complementation system
when using CMV-controlled expression cassettes in com-
bination with RC Ads. When using TETP as cancer cell-
selective promoter to restrict IL-2 and CD40L transgene
expression to melanoma cells, tight expression was
demonstrated, which was only 5 to 40-fold lower than
those from vectors controlled by the nonselective CMV
promoter. However, when combining the TETP-con-
trolled transgene vectors with RC wtAd5 or the AdΔEP-
TETP CRAd vector, very moderate trans-complementa-
tion enhancement was noticed in melanoma cells. At least
in part, this phenomenon may be due to Ad-mediated
down-regulation of the limiting transcription factor Mitf.
It remains to be investigated, whether this finding is
unique for the particular promoter system used here, or
whether it also occurs with other promoter systems. Tight
cancer cell-selective promoter control remains a highly
desirable feature to restrict transgene expression to the
targeted tumor tissue and avoid collateral damage.
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